{"slug":"selank-benzodiazepines","title":"selank benzodiazepines","body":"## Regeneration vs degeneration — where this fits\n\nbenzodiazepines represents tissue breakdown exceeding repair capacity. Most interventions manage symptoms. This article examines whether selank mechanisms address underlying repair deficits.\n\n## What is known\n\nStudied for anxiolytic pathways without classic benzodiazepine sedation.\n\nTarget condition: benzodiazepines.\nBody system: GABAergic suppression; does not rebuild neurochemistry..\n\n## Logic chain\n\n1. selank studied for anxiolytic pathways without classic benzodiazepine sedation..\n2. benzodiazepines involves gabaergic suppression; does not rebuild neurochemistry. dysfunction.\n3. If selank reaches the affected tissue, it may shift the repair/breakdown balance.\n4. This chain is tested in animal or lab models only.\n\n## Parent peptide claims relevant here\n\n- In a 2008 randomized study of 62 patients with GAD and neurasthenia, Selank showed anxiolytic efficacy comparable to medazepam on psychometric scales without reported sedation, cognitive impairment, tolerance or withdrawal.\n- Selank administration in rats alters expression of 45 neurotransmission-related genes at 1 hour and 22 genes at 3 hours, with positive correlation to GABA effects.\n- Commercial vendors and clinics market this compound (7 commercial/clinic sources catalogued) — marketing material, not evidence.\n- 2017 study showing Selank's anxiolytic effects comparable to benzodiazepines in rat stress model.\n- 2019 rat study on Selank protecting against alcohol-related memory issues via BDNF regulation.\n\n## Evidence tier\n\nPreclinical — animal and in vitro studies only. No published human trials for this specific combination.\n\n## What we do not know\n\n- Whether selank reaches benzodiazepines tissue at functional concentrations\n- Optimal dosing, route, and duration for this target\n- Interaction with standard-of-care treatments for benzodiazepines\n- Long-term safety profile in this population\n\n## Safety note\n\nAll peptide use for benzodiazepines is research-context only. Not medical advice. Consult a physician before any experimental compound.","register":"standard","tags":["peptide"],"category":null,"style":{},"claims":[{"id":"c1","text":"2025/2026 animal study (BALB/c mice) demonstrating that Selank combined with benzodiazepines (diazepam, mezapam) improves anxiolytic efficacy in elevated plus maze while reducing sedative/myorelaxant side effects; also mitigates locomotor decline with diazepam/olanzapine.","section":"what_is_known","tier":"speculative","source_ids":["s1"],"source_status":"sourced","why_material":"Materialized from orphan source s1 by ledger repair"},{"id":"c_map_selank-benzodiazepines","text":"Combinatorial mapping (transparent): selank vs benzodiazepines — regen=0.59, degen=0.68, Δ=-0.09. Method: layer_relevance(0.60) × evidence_factor(0.85); catalog.degen_score for Benzodiazepines.","section":"what_is_known","tier":"system"}],"sources":[{"id":"s1","type":"medical","url":"https://link.springer.com/article/10.1134/S1819712425700783","title":"Combined Action of Benzodiazepine Tranquilizers and Peptide Anxiolytic Selank in BALB/с Mice","quote":"Thus, it has been shown in animal experiments that selank enhances the anxiolytic effect and decreases the sedative and myorelaxant action of benzodiazepine tranquilizers.","summary":"2025/2026 animal study (BALB/c mice) demonstrating that Selank combined with benzodiazepines (diazepam, mezapam) improves anxiolytic efficacy in elevated plus maze while reducing sedative/myorelaxant side effects; also mitigates locomotor decline with diazepam/olanzapine.","author":"","publisher":"","date":"","claim_ids":["c1"]}],"prov":{"model":"grok/grok-4.3","action":"write"}}